Oncology Targeting blood cancers with high unmet need When it comes to myeloid malignancies such as acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), treatment progress has been slow.
R&D A Horizon of hope: UPLIZNA data, NMOSD, and ECTRIMS Neurological conditions like Multiple Sclerosis (MS) are an incredibly important area of research when it comes to drug discovery, but under that (sometim
News Appeal finds NICE must reconsider Alzheimer's drugs Lilly and Eisai's bid to secure NHS coverage of their Alzheimer's therapies has entered a new phase, after an appeal of last year's rejection by NICE.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.